FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380078201> ?p ?o ?g. }

• W4380078201 endingPage "695" @default.
• W4380078201 startingPage "694" @default.
• W4380078201 abstract "Introduction: Primary Central Nervous System Lymphoma (PCNSL) is a rare and intractable disease with a dismal prognosis. There is a paucity of data on Asian patients’ outcome, we aimed to review the clinicopathologic characteristics and prognostic factors influencing survival patterns of Asian patients with PCNSL. Methods: A retrospective review of adult PCNSL patients treated with frontline chemotherapy (ChT) consisting of methotrexate, vincristine, procarbazine (MVP) with or without rituximab (R-MVP), at two tertiary cancer centres in Singapore, between year 2000 and 2019 was conducted. We recorded data on demographics, ChT regimen, radiotherapy doses, treatment response and survival outcomes. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method. Univariate associations were derived using a Cox regression model. All statistical analyses were performed using R. Results: A total of 127 patients were analysed. Seventy-five (59%) were male and median age at diagnosis was 59 years (range: 20–78). Ethnic subgroups included 86 (67.7%) Chinese, 27 (21.3%) Malay, 7 (5.5%) Indian and 7 (5.5%) others. Median follow-up duration was 5.9 years (IQR 3.82 to 8.79 years). Most patients (n = 116, 91%) had ECOG performance status of 0-2. We observed that deep brain structure involvement was common (n = 99, 78%). Of the 80% patients with data on cerebrospinal fluid and intraocular involvements, these events were rare at 13.4% and 16.5% respectively. Classification by cell-of-origin revealed that 49.6% were of non-germinal centre (GC) subtype and 13.4% were GC subtype, while the rest were unknown. All patients received the MVP induction chemotherapy regimen with (40.9%) or without (59.1%) rituximab. Consolidation radiotherapy was administered to 100 patients (78.7%), while consolidation chemotherapy using cytarabine was administered to 69 patients (54.3%). None of the patients underwent upfront stem cell transplant. Approximately half the cohort (48.8%) received at least a single dose of intrathecal methotrexate. The median systemic methotrexate dose was 2.5 g/m2 and median radiotherapy dose was 36 Gy. The best overall treatment response rate was 94%, with 77% attaining complete response. Median OS was 4.5 years and median PFS was 3.6 years. 2-year PFS was 63.4% and 2-year OS was 76.9%. On univariate analysis, GC subtype was associated with improved PFS (HR = 0.13, 95% CI 0.03–0.55, p = 0.006) and OS (HR = 0.17, 95% CI 0.04-0.71, p = 0.015). Addition of rituximab to ChT and radiotherapy conferred survival advantage though this was not statistically significant. Keywords: aggressive B-cell non-Hodgkin lymphoma, extranodal non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract." @default.
• W4380078201 created "2023-06-10" @default.
• W4380078201 creator A5011817862 @default.
• W4380078201 creator A5012337680 @default.
• W4380078201 creator A5025267310 @default.
• W4380078201 creator A5032292277 @default.
• W4380078201 creator A5038667383 @default.
• W4380078201 creator A5041761505 @default.
• W4380078201 creator A5044506875 @default.
• W4380078201 creator A5057937956 @default.
• W4380078201 creator A5065920111 @default.
• W4380078201 creator A5069114400 @default.
• W4380078201 creator A5069197213 @default.
• W4380078201 creator A5073242341 @default.
• W4380078201 creator A5077860246 @default.
• W4380078201 creator A5087446798 @default.
• W4380078201 creator A5091237771 @default.
• W4380078201 date "2023-06-01" @default.
• W4380078201 modified "2023-10-12" @default.
• W4380078201 title "REAL WORLD EXPERIENCE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A MULTI‐ETHNIC ASIAN COHORT" @default.
• W4380078201 doi "https://doi.org/10.1002/hon.3165_547" @default.
• W4380078201 hasPublicationYear "2023" @default.
• W4380078201 type Work @default.
• W4380078201 citedByCount "0" @default.
• W4380078201 crossrefType "journal-article" @default.
• W4380078201 hasAuthorship W4380078201A5011817862 @default.
• W4380078201 hasAuthorship W4380078201A5012337680 @default.
• W4380078201 hasAuthorship W4380078201A5025267310 @default.
• W4380078201 hasAuthorship W4380078201A5032292277 @default.
• W4380078201 hasAuthorship W4380078201A5038667383 @default.
• W4380078201 hasAuthorship W4380078201A5041761505 @default.
• W4380078201 hasAuthorship W4380078201A5044506875 @default.
• W4380078201 hasAuthorship W4380078201A5057937956 @default.
• W4380078201 hasAuthorship W4380078201A5065920111 @default.
• W4380078201 hasAuthorship W4380078201A5069114400 @default.
• W4380078201 hasAuthorship W4380078201A5069197213 @default.
• W4380078201 hasAuthorship W4380078201A5073242341 @default.
• W4380078201 hasAuthorship W4380078201A5077860246 @default.
• W4380078201 hasAuthorship W4380078201A5087446798 @default.
• W4380078201 hasAuthorship W4380078201A5091237771 @default.
• W4380078201 hasBestOaLocation W43800782011 @default.
• W4380078201 hasConcept C126322002 @default.
• W4380078201 hasConcept C143998085 @default.
• W4380078201 hasConcept C144301174 @default.
• W4380078201 hasConcept C167135981 @default.
• W4380078201 hasConcept C2776694085 @default.
• W4380078201 hasConcept C2776755627 @default.
• W4380078201 hasConcept C2779112685 @default.
• W4380078201 hasConcept C2779338263 @default.
• W4380078201 hasConcept C2779429289 @default.
• W4380078201 hasConcept C2779714933 @default.
• W4380078201 hasConcept C2780653079 @default.
• W4380078201 hasConcept C2780739268 @default.
• W4380078201 hasConcept C2781173314 @default.
• W4380078201 hasConcept C2781413609 @default.
• W4380078201 hasConcept C38180746 @default.
• W4380078201 hasConcept C50382708 @default.
• W4380078201 hasConcept C509974204 @default.
• W4380078201 hasConcept C71924100 @default.
• W4380078201 hasConcept C72563966 @default.
• W4380078201 hasConceptScore W4380078201C126322002 @default.
• W4380078201 hasConceptScore W4380078201C143998085 @default.
• W4380078201 hasConceptScore W4380078201C144301174 @default.
• W4380078201 hasConceptScore W4380078201C167135981 @default.
• W4380078201 hasConceptScore W4380078201C2776694085 @default.
• W4380078201 hasConceptScore W4380078201C2776755627 @default.
• W4380078201 hasConceptScore W4380078201C2779112685 @default.
• W4380078201 hasConceptScore W4380078201C2779338263 @default.
• W4380078201 hasConceptScore W4380078201C2779429289 @default.
• W4380078201 hasConceptScore W4380078201C2779714933 @default.
• W4380078201 hasConceptScore W4380078201C2780653079 @default.
• W4380078201 hasConceptScore W4380078201C2780739268 @default.
• W4380078201 hasConceptScore W4380078201C2781173314 @default.
• W4380078201 hasConceptScore W4380078201C2781413609 @default.
• W4380078201 hasConceptScore W4380078201C38180746 @default.
• W4380078201 hasConceptScore W4380078201C50382708 @default.
• W4380078201 hasConceptScore W4380078201C509974204 @default.
• W4380078201 hasConceptScore W4380078201C71924100 @default.
• W4380078201 hasConceptScore W4380078201C72563966 @default.
• W4380078201 hasIssue "S2" @default.
• W4380078201 hasLocation W43800782011 @default.
• W4380078201 hasOpenAccess W4380078201 @default.
• W4380078201 hasPrimaryLocation W43800782011 @default.
• W4380078201 hasRelatedWork W2007109776 @default.
• W4380078201 hasRelatedWork W2059728253 @default.
• W4380078201 hasRelatedWork W2071456612 @default.
• W4380078201 hasRelatedWork W2080319707 @default.
• W4380078201 hasRelatedWork W2394645303 @default.
• W4380078201 hasRelatedWork W2409059610 @default.
• W4380078201 hasRelatedWork W2417057455 @default.
• W4380078201 hasRelatedWork W2916489774 @default.
• W4380078201 hasRelatedWork W2980860471 @default.
• W4380078201 hasRelatedWork W4377939980 @default.
• W4380078201 hasVolume "41" @default.
• W4380078201 isParatext "false" @default.
• W4380078201 isRetracted "false" @default.
• W4380078201 workType "article" @default.